Partnership Opportunities

Next-Generation Newborn Screening to Improve Treatment Efficacy

Improving therapy for lysosomal storage diseases using a proteomic method for dried blood samples

Technology Overview

Sihoun Hahn 220x180Dr. Sihoun Hahn

Of the 4 million babies born in the United States every year, as many as 1 in 5,000 have a lysosomal storage or transport disease. Without treatment, these diseases, which include Hunter and Hurler syndromes, cystinosis and Tay-Sachs and Gaucher disease, can have severe developmental consequences. Treatment options include enzyme replacement therapy (ERT), which must be administered as soon as possible after diagnosis.

In some children, therapeutic effectiveness is compromised because their immune system produces antibodies against ERT. This occurs, for example, in as many as 1 in 4 infants with Pompe disease, for whom poor response to treatment can lead to irreparable cardiac damage. The production of ERT-neutralizing antibodies can be averted with immunomodulating therapy before beginning ERT. Testing infants for their potential to generate neutralizing antibodies, however, can mean delaying ERT for months.

Dr. Hahn and colleagues recently published a proof-of-concept paper on a rapid, proteomics-based method that could determine an infant’s susceptibility to producing neutralizing antibodies. The method is peptide immunoaffinity enrichment coupled to selected reaction monitoring (immuno-SRM). Immuno-SRM begins with dried blood spots on filter paper, which are routinely collected at birth. Proteins from the samples are enzymatically digested into peptides. Immunoaffinity chromatography enriches for peptides characteristic of a specific lysosomal disease, which are quantified by mass spectrometry (MS). Immuno-SRM uses standard MS instruments available in many clinical laboratories.

Hahn’s group has a panel of antibodies for immuno-SRM that could quickly determine when children who are eligible for ERT should first undergo immunomodulation. Hahn participated in clinical trials for the U.S. Food and Drug Administration on Luminzyme, the Genzyme ERT for Pompe disease. He is interested in partnering on developing and validating immuno-SRM assays to determine which newborns with lysosomal storage diseases would benefit from immunomodulation before starting ERT.

Stage of Development

  • Pre-clinical validation

Partnering Opportunities

  • Collaborative research opportunity
  • Sponsored research agreement
  • High throughput screening
  • Kit Development
  • Consultation agreement
  • Clinical Trial


  1. Jung S, Whiteaker JR, Zhao L, Yoo HW, Paulovich AG, Hahn SHQuantification of ATP7B Protein in Dried Blood Spots by Peptide Immuno-SRM as a Potential Screen for Wilson’s DiseaseJ Proteome Res 2017. 16(2):862-871. doi: 10.1021/acs.jproteome.6b00828.
  2. Jung S, Tran NT, Gospe SM Jr, Hahn SHPreliminary investigation of the use of newborn dried blood spots for screening pyridoxine-dependent epilepsy by LC-MS/MSMol Genet Metab. 2013. 110(3):237–40. doi: 10.1016/j.ymgme.2013.07.017.
  3. Kerfoot, SA, Jung S, Golob K, Torgerson RT, Hahn SHTryptic peptide screening for primary immunodeficiency disease by LC/MS-MSProteomics Clinical Applications. 2012. 6 (7-8): 394–402. doi: 10.1002/prca.201100096.

Learn More

To learn more about partnering with Seattle Children’s Research Institute on this or other projects, please contact:

Dr. Elizabeth Aylward, Director 
Office of Science-Industry Partnerships 
Seattle Children’s Research Institute 
818 Stewart Street, Suite 603
Seattle, WA 98101